🏢 官网IRMNKDCodex · 实盘不做把握 9/10
北京时间·🕒 发布 04:01:00·⟳ 抓取 04:01:59 +59s·⚡ 决策 07-29 04:02:33 +34s·91.1 天前
MannKind宣布将于8月5日盘后发布二季度财报并召开电话会
本次只是公司预告二季度财报披露和电话会时间，没有披露业绩、指引、订单、监管进展或其它可交易新增事实。
📄 原文MNKD↗ 原文
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , July 28, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , t…
不做 MannKind（MNKD.US）
例行财报发布时间公告，不披露业绩或业务更新内容，方向不明且没有可交易edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 low · price-in 风险 low ↗
关键理由
- 本次只是公司预告二季度财报披露和电话会时间，没有披露业绩、指引、订单、监管进展或其它可交易新增事实。
主要风险
- 真正影响交易判断的信息要等2026年8月5日盘后财报和业务更新披露后再评估。
原文全文
展开原文 · 1,407 字
DANBURY, Conn.
and
WESTLAKE VILLAGE, Calif.
,
July 28, 2026
(GLOBE NEWSWIRE) --
MannKind Corporation
(Nasdaq: MNKD)
, today announced that the Company will report second quarter 2026 financial results after market close on
Wednesday, August 5, 2026
.
MannKind’s management team will host a conference call at
4:30 p.m. Eastern Time
to review the financial results and provide a business update.
The webcast of the conference call will be accessible via a link on MannKind’s website at
https://investors.mannkindcorp.com/events-and-presentations
. A replay will be available in the same location within 24 hours following the call and will be accessible for approximately 90 days.
About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
Learn more at mannkindcorp.com.
Contacts:
Investor Relations
Kate Miranda
(617) 921-5461
Email: ir@mnkd.com
Media Relations
Christie Iacangelo
(818) 292-3500
Email: media@mnkd.com
and
WESTLAKE VILLAGE, Calif.
,
July 28, 2026
(GLOBE NEWSWIRE) --
MannKind Corporation
(Nasdaq: MNKD)
, today announced that the Company will report second quarter 2026 financial results after market close on
Wednesday, August 5, 2026
.
MannKind’s management team will host a conference call at
4:30 p.m. Eastern Time
to review the financial results and provide a business update.
The webcast of the conference call will be accessible via a link on MannKind’s website at
https://investors.mannkindcorp.com/events-and-presentations
. A replay will be available in the same location within 24 hours following the call and will be accessible for approximately 90 days.
About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
Learn more at mannkindcorp.com.
Contacts:
Investor Relations
Kate Miranda
(617) 921-5461
Email: ir@mnkd.com
Media Relations
Christie Iacangelo
(818) 292-3500
Email: media@mnkd.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。